Roivant Sciences Forecast, price target & analysts
Roivant Sciences Target price 2025 - Analyst rating & recommendation
Roivant Sciences Classifications & Recommendation:
Roivant Sciences Price Target
| Target Price | $16.00 |
| Price | $10.68 |
| Potential |
49.81%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Roivant Sciences 2026 .
The average Roivant Sciences target price is $16.00.
This is
49.81%
register free of charge
$18.00
68.54%
register free of charge
$12.00
12.36%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Roivant Sciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2026 of
49.81%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 124.80 | 141.38 |
| 103.66% | 13.29% | |
| EBITDA Margin | -847.68% | -719.69% |
| 50.58% | 15.10% | |
| Net Margin | 3,015.76% | -202.58% |
| 280.85% | 106.72% |
6 Analysts have issued a sales forecast Roivant Sciences 2025 . The average Roivant Sciences sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Roivant Sciences EBITDA forecast 2025. The average Roivant Sciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Roivant Sciences Analysts have issued a net profit forecast 2025. The average Roivant Sciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 5.23 | -0.40 |
| 468.31% | 107.65% | |
| P/E | negative | |
| EV/Sales | 20.64 |
5 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Roivant Sciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Roivant Sciences...
Current Roivant Sciences Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Feb 11 2025 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Nov 13 2024 |
| Cantor Fitzgerald | ➜ Overweight | Unchanged | Sep 19 2024 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Sep 19 2024 |
| B of A Securities | Neutral ➜ Neutral | Unchanged | Sep 11 2024 |
| HC Wainwright & Co. | Buy ➜ Buy | Unchanged | Sep 11 2024 |
| Cantor Fitzgerald | ➜ Overweight | Unchanged | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Feb 11 2025 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Nov 13 2024 |
|
Unchanged
Cantor Fitzgerald: ➜ Overweight
|
Sep 19 2024 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Sep 19 2024 |
|
Unchanged
B of A Securities: Neutral ➜ Neutral
|
Sep 11 2024 |
|
Unchanged
HC Wainwright & Co.: Buy ➜ Buy
|
Sep 11 2024 |
|
Unchanged
Cantor Fitzgerald: ➜ Overweight
|
Sep 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
